China holds a choke point on the global pharmaceutical supply chain, being the sole source for key ingredients in hundreds of US medicines. This leverage could be used to restrict supply, creating shortages and price hikes, opening a new, sensitive front in geopolitical tensions.

The steep tariff on foreign-made drugs is an aggressive tactic to compel pharmaceutical companies to bring manufacturing back to the US. It aims to solve two critical problems: reducing strategic dependency on adversaries like China and rebuilding domestic manufacturing jobs.

The current pharma tariffs are based on a "national security provision" (Section 232), which has a more secure legal footing than prior, successfully challenged tariff orders. Drawing parallels to long-standing steel and China tariffs, companies should strategize for this as a permanent feature of the trade landscape, not a temporary policy.

Effective tariff reduction requires a deep dive into three fundamental customs compliance areas: country of origin rules, correct tariff code classification, and customs valuation methods. Experts suggest the biggest savings opportunities for many firms lie in scrutinizing and optimizing these often-overlooked details to legitimately lower their dutiable base.

The push for supply chain diversification and reduced reliance on China is not a new phenomenon. The COVID-19 pandemic first exposed the critical risks of single-source dependency. Recent tariff threats are not the origin of this strategic realignment but rather a powerful accelerant, forcing companies to act on plans already in motion.

The biopharma outsourcing sector has proven surprisingly resilient to international tariffs. Instead of absorbing costs, well-funded European companies are bypassing tariffs altogether by investing in and building new production facilities directly on U.S. soil, effectively onshoring their manufacturing.

Unlike large firms making US investment pledges for exemptions, smaller drug makers must rely on nuanced, capital-light tactics. These include unbundling costs to lower dutiable value, using duty drawback programs for re-exported goods, and leveraging foreign trade zones to survive high tariff rates without massive infrastructure spending.

The proposed pharma tariffs exempt companies with MFN (Most Favored Nation) deals, which are primarily large players. This gives them a strategic advantage in M&A, as they can acquire smaller, tariff-burdened companies and absorb their assets into a tariff-free structure, creating favorable deal dynamics.

While US tariff policies aim to bring pharmaceutical production back onshore, the immediate beneficiaries are likely to be contract manufacturers. Building new proprietary facilities is a slow and expensive process, so companies will lean on agile contract partners to quickly diversify their supply chains in the interim.